Alexander W. Hauswirth

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Comparing functional and genomic-based precision medicine in blood cancer patients.

Comparing functional and genomic-based precision medicine in blood cancer patients.

Journal: HemaSphere

Published: February 20, 2025

BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.

BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.

Journal: American journal of hematology

Published: January 30, 2024

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia.

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia.

Journal: Cells

Published: August 29, 2022

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL).

Journal: Cancers

Published: July 20, 2022

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.

Journal: American journal of hematology

Published: June 20, 2022

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Journal: Cancer discovery

Published: April 26, 2021

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 14, 2021

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Journal: Neoplasia (New York, N.Y.)

Published: February 08, 2018

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Journal: Blood

Published: May 17, 2017

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Journal: Oncotarget

Published: December 21, 2016

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Journal: Leukemia

Published: May 10, 2016

Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.

Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: January 14, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026